Human ITP clinical trials have been performed based on observations of clinical uses of drugs, other than on mechanism studies in preclinical models, many studies were stopped because of unexpected complications. So there was need to develop ideal animal model of ITP to improve the understanding of the pathophysiology and the mechanisms of action of therapeutics. In this review, the history of animal models of ITP was retrospected, two modeling methods inducing passive and active models, especially transgenic rice model which can more accurately represent human disease pathophysiology, and their application in study of ITP were summarized. An animal model for human immune thrombocytopenia allows detailed studies of the mechanism, kinetics, and therapy of human immune thrombocytopenia.